CD274 and non-small cell lung carcinoma: A pooled analysis of KEYNOTE-001 (phase 1), 010 (phase 2/3), 024 (phase 3), and 042 (phase 3) studies evaluated 3170 patients with stage IV NSCLC and PD-L1 positive status, of whom 293 (9.2%) had BM.